background preloader


Facebook Twitter

Useful Resources

Action Potential & Epilepsy. Pharmacology - ANTIEPILEPTIC DRUGS (MADE EASY) Summary of antiepileptic drugs. Epileptic seizures explained | Epilepsy Action. Epilepsy Action would like to place cookies on your computer to help us make this website better. Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links. We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable. By using our site you accept the terms of our Privacy Policy. (One cookie will be set to store your preference) (Ticking this sets a cookie to hide this popup if you then hit close. About this tool About Cookie Control.

Irish Epilepsy & Pregnancy Register. Valproate (Epilim) - Valproate (Epilim) If you have previously been prescribed or if you are currently taking valproate (Epilim®) and have any concerns about it, please contact your GP or your prescriber for advice and guidance. You will also find detailed questions and answers about valproate, or Epilim®, below. Valproate is a medicine licensed in Ireland to treat epilepsy and bipolar disorder. It is known as Epilim® in Ireland and other brand names exist in other countries. If a woman becomes pregnant while taking valproate (Epilim®), their baby is at risk of serious birth defects and developmental disorders. In February 2018, the European Medicines Agency recommended new restrictions on the use of valproate (Epilim) including a Pregnancy Prevention Programme.

Valproate (Epilim®) must no longer be used in women or girls of childbearing potential unless the terms of the Valproate Pregnancy Prevention Programme are followed. Questions and Answers for patients: What is valproate (Epilim®)? What are the risks? SUDEP | Epilepsy Ireland. Sudden Unexpected Death in Epilepsy (SUDEP) is the "sudden unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in an individual with epilepsy, with or without evidence of a seizure and excluding documented status epilepticus where post-mortem examination does not reveal a cause for death".SUDEP is uncommon. Between 21-44 people are believed to die from SUDEP each year in Ireland. SUDEP is connected to seizures but what exactly causes it is unknown. The most likely explanation is that a seizure interferes with the part of the brain that controls breathing or the heart. Who is most at risk? The risk of SUDEP varies from low to very low, but, for a small number of people the risk may be higher.

Keep perspective on risk It is important to put safety risks in perspective. Summary of risk factors for SUDEP: Summary of advice to reduce your risk: Epilepsy Lighthouse Project - eHealth Ireland. This project is being delivered by eHealth Ireland which is part of the HSE, in collaboration with Royal College of Surgeons in Ireland, Epilepsy Ireland and Beaumont Hospital. To have epilepsy is to have a tendency to have recurring seizures. Anyone can have a seizure, if the brain is exposed to a strong enough stimulus.

We know that about 1 in every 20 people will have a single seizure at some time during their lives. There are ~37,000 people with Epilepsy in Ireland. The Epilepsy Lighthouse project will build upon the success of the epilepsy EPR started in Beaumont Hospital. Worldwide the instances of misdiagnosis can be as high as 20% in a specialist clinic and between 30-50% in general clinics. This project will show the move away from the traditional “one size fits all” clinical treatments and instead focus individualized treatments where the patient is at the centre. Below you can see a video explaining more about this project and how it improves lives: Improving Lives with Technology - HSE Lighthouse Project.